Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation.

Pediatric medulloblastoma is considered a highly heterogeneous disease and a new strategy of risk stratification to optimize therapeutic outcomes is required. We aimed to investigate a new risk-stratification approach based on expression profiles of medulloblastoma cohorts. We analyzed gene expression profiles of 30 primary medulloblastomas and detected strong evidence that poor survival outcome was significantly associated with mRNA expression profiles of 17p loss. However, it was not supported in independent cohorts from previously published data (n = 100). We speculated that this discrepancy might come from complex conditions of two important prognostic determinants: loss of tumor suppressors (chromosome 17p) and high expression of oncogenes c-myc (MYCC) or N-myc (MYCN). When patients were stratified into 5 or 7 subgroups based on simultaneous consideration of these 2 factors while defining the Wnt group as independent, obviously different survival expectancies were detected between the subgroups. For instance, predicted 5-year survival probabilities ranged from 19% to 81% in the 5 subgroups. We also found that age became a significant prognostic marker after adjusting for 17p, MYCC, and MYCN status. Diminished survival in age <3 years was more substantial in subgroups with high expression of MYCC, MYCN, or 17p loss but not in other subgroups, indicating that poor survival outcome might be synergistically affected by these 3 factors. Here we suggest a more tailored subgrouping system based on expression profiles of chromosome 17p, MYCC, and MYCN, which could provide the basis for a novel risk-stratification strategy in pediatric medulloblastoma.

[1]  J. Mesirov,et al.  Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Hendrik Witt,et al.  Medulloblastoma comprises four distinct molecular variants. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Chae-Yong Kim,et al.  Cerebrospinal fluid M staging for medulloblastoma: reappraisal of Chang's M staging based on the CSF flow. , 2011, Neuro-oncology.

[4]  Yiai Tong,et al.  Subtypes of medulloblastoma have distinct developmental origins , 2010, Nature.

[5]  Eric C. Holland,et al.  Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma , 2010, Nature Reviews Cancer.

[6]  J. Ross,et al.  Multigene Classifiers, Prognostic Factors, and Predictors of Breast Cancer Clinical Outcome , 2009, Advances in anatomic pathology.

[7]  Emmanuel Barillot,et al.  Beta‐catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics , 2009, The Journal of pathology.

[8]  Marieke E. Timmerman,et al.  Smoothing waves in array CGH tumor profiles , 2009, Bioinform..

[9]  Axel Benner,et al.  Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Clifford,et al.  The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials , 2009, British journal of neurosurgery.

[11]  Dirk Troost,et al.  Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features , 2008, PloS one.

[12]  Robert Gentleman,et al.  Bioconductor Case Studies , 2008 .

[13]  E. Holland,et al.  c-Myc and β-catenin cooperate with loss of p53 to generate multiple members of the primitive neuroectodermal tumor family in mice , 2008, Oncogene.

[14]  J. Rutka,et al.  The molecular genetics of medulloblastoma: an assessment of new therapeutic targets , 2008, Neurosurgical Review.

[15]  Peter Lichter,et al.  The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma , 2008, International journal of cancer.

[16]  Renee F Wilson,et al.  Systematic Review: Gene Expression Profiling Assays in Early-Stage Breast Cancer , 2008, Annals of Internal Medicine.

[17]  S. Pomeroy,et al.  Gain of 1q Is a Potential Univariate Negative Prognostic Marker for Survival in Medulloblastoma , 2007, Clinical Cancer Research.

[18]  T. MacDonald,et al.  Medulloblastoma in childhood: new biological advances , 2007, The Lancet Neurology.

[19]  John Y. H. Kim,et al.  Overexpressed TP73 induces apoptosis in medulloblastoma , 2007, BMC Cancer.

[20]  Hidetoshi Shimodaira,et al.  Pvclust: an R package for assessing the uncertainty in hierarchical clustering , 2006, Bioinform..

[21]  D. Pearson,et al.  High-Resolution Array-Based Comparative Genomic Hybridization of Medulloblastomas and Supratentorial Primitive Neuroectodermal Tumors , 2006, Journal of neuropathology and experimental neurology.

[22]  T. Curran,et al.  Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  B. Korn,et al.  Isochromosome breakpoints on 17p in medulloblastoma are flanked by different classes of DNA sequence repeats , 2006, Genes, chromosomes & cancer.

[24]  J. Rutka,et al.  Array CGH analysis of pediatric medulloblastomas , 2006, Genes, chromosomes & cancer.

[25]  Axel Benner,et al.  Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Claire L Weston,et al.  beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Biegel,et al.  Isochromosome 17q Is a Negative Prognostic Factor in Poor-Risk Childhood Medulloblastoma Patients , 2005, Clinical Cancer Research.

[28]  D. Ellison,et al.  Combined Histopathological and Molecular Cytogenetic Stratification of Medulloblastoma Patients , 2004, Clinical Cancer Research.

[29]  S. Scherer,et al.  Failure of a medulloblastoma-derived mutant of SUFU to suppress WNT signaling , 2004, Oncogene.

[30]  F. Kokocinski,et al.  Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. , 2004, Cancer research.

[31]  C. Dang,et al.  Histopathological and Molecular Prognostic Markers in Medulloblastoma: c‐myc, N‐myc, TrkC, and Anaplasia , 2004, Journal of neuropathology and experimental neurology.

[32]  S. Ishii,et al.  Oncogenic Activation of c-Myb Correlates with a Loss of Negative Regulation by TIF1β and Ski*[boxs] , 2004, Journal of Biological Chemistry.

[33]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[34]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[35]  D. Ellison,et al.  Classifying the medulloblastoma: insights from morphology and molecular genetics , 2002, Neuropathology and applied neurobiology.

[36]  T. Poggio,et al.  Prediction of central nervous system embryonal tumour outcome based on gene expression , 2002, Nature.

[37]  J. Crolla,et al.  Clinical and molecular stratification of disease risk in medulloblastoma , 2001, British Journal of Cancer.

[38]  Nello Cristianini,et al.  Support vector machine classification and validation of cancer tissue samples using microarray expression data , 2000, Bioinform..

[39]  R. McLendon,et al.  Characterization of chromosome 17 abnormalities in medulloblastomas , 2000, Acta Neuropathologica.

[40]  J. Trojanowski,et al.  TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  L. Rorke,et al.  Medulloblastoma: clinical and biologic aspects. , 1999, Neuro-oncology.

[42]  Tracey A. Cho,et al.  Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas. , 1999, Cancer research.

[43]  L. Chin,et al.  Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression , 1997, nature.

[44]  J. Biegel,et al.  Prognostic significance of chromosome 17p deletions in childhood primitive neuroectodermal tumors (medulloblastomas) of the central nervous system. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  C. Metz,et al.  A receiver operating characteristic partial area index for highly sensitive diagnostic tests. , 1996, Radiology.

[46]  J. Biegel,et al.  Isochromosome 17q demonstrated by interphase fluorescence in situ hybridization in primitive neuroectodermal tumors of the central nervous system , 1995, Genes, chromosomes & cancer.

[47]  Genes, chromosomes & cancer , 1995 .

[48]  S. Pomeroy,et al.  Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Jane Fridlyand,et al.  Bioinformatics Original Paper a Comparison Study: Applying Segmentation to Array Cgh Data for Downstream Analyses , 2022 .

[50]  S. Elledge,et al.  Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease , 2003, Nature Genetics.

[51]  S. Pomeroy,et al.  Identification of PATCHED mutations in medulloblastomas by direct sequencing. , 2000, Human mutation.

[52]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[53]  A. Olshen,et al.  A Faster Circular Binary Segmentation Algorithm for the Analysis of Array Cgh Data , 2022 .